Stampacchia: why biopharmas should think more about secondary venture investments

Sixteen years after pioneering direct secondary transactions for healthcare investments, Omega Funds founder Otello Stampacchia thinks industry still has a lot to learn about these deals. In a conversation with BioCentury, Stampacchia lays out how the biotech secondaries landscape is evolving, and why management teams stand to benefit from a proactive approach to the transactions.

Originally founded in 2004 with secondaries as a core part of its strategy, Omega Funds now views the deals as one of many instruments at its disposal. ...